Medtronic (NYSE:MDT), the maker of new innovative medical devices, announced the U.S. launch of a new remote glucose monitor that allows caregivers to be aware of glucose levels of the patient in another room.
Describing mySentry as a first-of-its-kind monitor, Medtronic said that it would allow parents and other caregivers to know in real time glucose levels from a type 1 diabetes patient using the compnay’s Minimed Paradigm Real Time Revel System. The Minimed Paradigm Real Time System is the first U.S. Food and Drug Administration-approved integrated insulin pump and continuous glucose monitoring system.
The product shows real-time insulin pump status and glucose trends. It can also give alerts and alarms to parents and other caregivers in their bedroom while the patient — whether an adult or child — sleeps in another room.
One big fear of caring for diabetics is that their insulin levels may drop in the middle of the night. This makes caregivers and parents of diabetics wake up several times in the night to make sure that the glucose levels are where they should be. Medtronic’s mySentry eliminates that problem of regular night-time waking by alerting caregivers that a patient’s insulin level is dropping. They can then take action to prevent an episode of hypoglycemia.
“We’re excited to bring this new innovation to market that could give caregivers greater peace of mind. The mySentry Remote Glucose Monitor is the first step toward our vision to develop an entire category of Connected Care products that help people more proactively manage their diabetes by making it easier and more convenient to access the wealth of information captured by our integrated insulin pump and continuous glucose monitoring (CGM) system,” said Greg Meehan, Medtronic’s vice president and general manager of the Continuous Glucose Monitoring business at Medtronic, in a news release.
